In a ‘Real-World’, Clinic-Based Community Setting, Sorafenib Dose of 400 mg/day is as Effective as Standard Dose of 800 mg/day in Patients with Advanced Hepatocellular Carcimona, with Better Tolerance and Similar Survival
BACKGROUND: Sorafenib, an oral multityrosine kinase inhibitor, has been approved for treatment of unresectable hepatocellular carcinoma (HCC). British Columbia (BC) was the first province in Canada to provide drug coverage for sorafenib.
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2013/170546 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850209127554351104 |
|---|---|
| author | Alexandra Shingina Al Moutaz Hashim Mazhar Haque Michael Suen Eric M Yoshida Sharlene Gill Fergal Donnellan Alan A Weiss |
| author_facet | Alexandra Shingina Al Moutaz Hashim Mazhar Haque Michael Suen Eric M Yoshida Sharlene Gill Fergal Donnellan Alan A Weiss |
| author_sort | Alexandra Shingina |
| collection | DOAJ |
| description | BACKGROUND: Sorafenib, an oral multityrosine kinase inhibitor, has been approved for treatment of unresectable hepatocellular carcinoma (HCC). British Columbia (BC) was the first province in Canada to provide drug coverage for sorafenib. |
| format | Article |
| id | doaj-art-95cebbf611d04a0a8cdf5e2a83ce333b |
| institution | OA Journals |
| issn | 0835-7900 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-95cebbf611d04a0a8cdf5e2a83ce333b2025-08-20T02:10:06ZengWileyCanadian Journal of Gastroenterology0835-79002013-01-0127739339610.1155/2013/170546In a ‘Real-World’, Clinic-Based Community Setting, Sorafenib Dose of 400 mg/day is as Effective as Standard Dose of 800 mg/day in Patients with Advanced Hepatocellular Carcimona, with Better Tolerance and Similar SurvivalAlexandra Shingina0Al Moutaz Hashim1Mazhar Haque2Michael Suen3Eric M Yoshida4Sharlene Gill5Fergal Donnellan6Alan A Weiss7Department of Medicine, Division of Gastroenterology, Department of Obstetrics and Gynecology, University of British Columbia, CanadaDepartment of Medicine, Division of Gastroenterology, Department of Obstetrics and Gynecology, University of British Columbia, CanadaDepartment of Medicine, Division of Gastroenterology, Department of Obstetrics and Gynecology, University of British Columbia, CanadaDepartment of Medical Oncology, The British Columbia Cancer Agency, Vancouver, British Columbia, CanadaDepartment of Medicine, Division of Gastroenterology, Department of Obstetrics and Gynecology, University of British Columbia, CanadaDepartment of Medical Oncology, The British Columbia Cancer Agency, Vancouver, British Columbia, CanadaDepartment of Medicine, Division of Gastroenterology, Department of Obstetrics and Gynecology, University of British Columbia, CanadaDepartment of Medicine, Division of Gastroenterology, Department of Obstetrics and Gynecology, University of British Columbia, CanadaBACKGROUND: Sorafenib, an oral multityrosine kinase inhibitor, has been approved for treatment of unresectable hepatocellular carcinoma (HCC). British Columbia (BC) was the first province in Canada to provide drug coverage for sorafenib.http://dx.doi.org/10.1155/2013/170546 |
| spellingShingle | Alexandra Shingina Al Moutaz Hashim Mazhar Haque Michael Suen Eric M Yoshida Sharlene Gill Fergal Donnellan Alan A Weiss In a ‘Real-World’, Clinic-Based Community Setting, Sorafenib Dose of 400 mg/day is as Effective as Standard Dose of 800 mg/day in Patients with Advanced Hepatocellular Carcimona, with Better Tolerance and Similar Survival Canadian Journal of Gastroenterology |
| title | In a ‘Real-World’, Clinic-Based Community Setting, Sorafenib Dose of 400 mg/day is as Effective as Standard Dose of 800 mg/day in Patients with Advanced Hepatocellular Carcimona, with Better Tolerance and Similar Survival |
| title_full | In a ‘Real-World’, Clinic-Based Community Setting, Sorafenib Dose of 400 mg/day is as Effective as Standard Dose of 800 mg/day in Patients with Advanced Hepatocellular Carcimona, with Better Tolerance and Similar Survival |
| title_fullStr | In a ‘Real-World’, Clinic-Based Community Setting, Sorafenib Dose of 400 mg/day is as Effective as Standard Dose of 800 mg/day in Patients with Advanced Hepatocellular Carcimona, with Better Tolerance and Similar Survival |
| title_full_unstemmed | In a ‘Real-World’, Clinic-Based Community Setting, Sorafenib Dose of 400 mg/day is as Effective as Standard Dose of 800 mg/day in Patients with Advanced Hepatocellular Carcimona, with Better Tolerance and Similar Survival |
| title_short | In a ‘Real-World’, Clinic-Based Community Setting, Sorafenib Dose of 400 mg/day is as Effective as Standard Dose of 800 mg/day in Patients with Advanced Hepatocellular Carcimona, with Better Tolerance and Similar Survival |
| title_sort | in a real world clinic based community setting sorafenib dose of 400 mg day is as effective as standard dose of 800 mg day in patients with advanced hepatocellular carcimona with better tolerance and similar survival |
| url | http://dx.doi.org/10.1155/2013/170546 |
| work_keys_str_mv | AT alexandrashingina inarealworldclinicbasedcommunitysettingsorafenibdoseof400mgdayisaseffectiveasstandarddoseof800mgdayinpatientswithadvancedhepatocellularcarcimonawithbettertoleranceandsimilarsurvival AT almoutazhashim inarealworldclinicbasedcommunitysettingsorafenibdoseof400mgdayisaseffectiveasstandarddoseof800mgdayinpatientswithadvancedhepatocellularcarcimonawithbettertoleranceandsimilarsurvival AT mazharhaque inarealworldclinicbasedcommunitysettingsorafenibdoseof400mgdayisaseffectiveasstandarddoseof800mgdayinpatientswithadvancedhepatocellularcarcimonawithbettertoleranceandsimilarsurvival AT michaelsuen inarealworldclinicbasedcommunitysettingsorafenibdoseof400mgdayisaseffectiveasstandarddoseof800mgdayinpatientswithadvancedhepatocellularcarcimonawithbettertoleranceandsimilarsurvival AT ericmyoshida inarealworldclinicbasedcommunitysettingsorafenibdoseof400mgdayisaseffectiveasstandarddoseof800mgdayinpatientswithadvancedhepatocellularcarcimonawithbettertoleranceandsimilarsurvival AT sharlenegill inarealworldclinicbasedcommunitysettingsorafenibdoseof400mgdayisaseffectiveasstandarddoseof800mgdayinpatientswithadvancedhepatocellularcarcimonawithbettertoleranceandsimilarsurvival AT fergaldonnellan inarealworldclinicbasedcommunitysettingsorafenibdoseof400mgdayisaseffectiveasstandarddoseof800mgdayinpatientswithadvancedhepatocellularcarcimonawithbettertoleranceandsimilarsurvival AT alanaweiss inarealworldclinicbasedcommunitysettingsorafenibdoseof400mgdayisaseffectiveasstandarddoseof800mgdayinpatientswithadvancedhepatocellularcarcimonawithbettertoleranceandsimilarsurvival |